Systemic gene delivery following intravenous administration of AAV9 to fetal and neonatal mice and late-gestation nonhuman primates by Mattar, CN et al.
The FASEB Journal • Research Communication
Systemic gene delivery following intravenous
administration of AAV9 to fetal and neonatal mice
and late-gestation nonhuman primates
Citra N. Mattar,* Andrew M. S. Wong,† Klemens Hoefer,† Maria E. Alonso-Ferrero,‡
Suzanne M. K. Buckley,§ Steven J. Howe,‡ Jonathan D. Cooper,† Simon N. Waddington,§,{,1
Jerry K. Y. Chan,*,k,#,2 and Ahad A. Rahim**,2
*Experimental Fetal Medicine Group, Department of Obstetrics and Gynaecology, National University of
Singapore, Singapore; †Pediatric Storage Disorders Laboratory, Institute of Psychiatry, King’s College
London, London, United Kingdom; ‡University College London (UCL) Institute for Child Health,
§Gene Transfer Technology Group, Institute for Women’s Health, and **Department of Pharmacology,
UCL School of Pharmacy, University College London, London, United Kingdom; {Antiviral Gene
Therapy Research Unit, Faculty of Health Sciences, University of the Witswatersrand, Johannesburg,
South Africa; kDepartment of Reproductive Medicine, KK Women’s and Children’s Tower, Singapore;
and #Cancer and Stem Cell Biology, Duke-NUS Graduate Medical School, Singapore
ABSTRACT Several acute monogenic diseases affect
multiple body systems, causing death in childhood. The
development of novel therapies for such conditions is
challenging. However, improvements in gene delivery
technology mean that gene therapy has the potential to
treat such disorders. We evaluated the ability of the AAV9
vector to mediate systemic gene delivery after intravenous
administration to perinatal mice and late-gestation non-
human primates (NHPs). Titer-matched single-stranded
(ss) and self-complementary (sc) AAV9 carrying the green
ﬂuorescent protein (GFP) reporter gene were intrave-
nously administered to fetal and neonatal mice, with non-
injected age-matched mice used as the control. Extensive
GFP expression was observed in organs throughout the
body, with the epithelial andmuscle cells being particularly
well transduced. ssAAV9 carrying the WPRE sequence
mediated signiﬁcantly more gene expression than its sc
counterpart, which lacked the woodchuck hepatitis virus
posttranscriptional regulatory element (WPRE) sequence.
To examine a realistic scale-up to larger models or poten-
tially patients for such an approach, AAV9 was in-
travenously administered to late-gestation NHPs by using
a clinically relevant protocol. Widespread systemic gene
expression was measured throughout the body, with cel-
lular tropisms similar to those observed in the mouse
studies and no observable adverse events. This study con-
ﬁrms that AAV9 can safely mediate systemic gene delivery
in small and large animalmodels and supports its potential
use in clinical systemic gene therapy protocols.—Mattar,
C. N., Wong, A. M. S., Hoefer, K., Alonso-Ferrero, M. E.,
Buckley, S. M. K., Howe, S. J., Cooper, J. D., Waddington,
S. N., Chan, J. K. Y., Rahim, A. A. Systemic gene delivery
following intravenous administration of AAV9 to fetal
and neonatal mice and late-gestation nonhuman pri-
mates. FASEB J. 29, 3876–3888 (2015). www.fasebj.org
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MONOGENIC DISORDERS AFFECTING MULTIPLE ORGANS of the body
present a particularly challenging target for developing
novel therapies. In some cases, clinical treatments are al-
ready available to tackle such conditions. Enzyme re-
placement therapy (ERT) is an example and has been
successful in treating some lysosomal storage disorders
(LSDs) [e.g., type I Gaucher disease (GD) and Fabry dis-
ease].However, the uptake of recombinant enzymes is not
efﬁcient in all cells, as is evident in patients with GD who
receive regular intravenous infusions of recombinant en-
zyme but who still experience severe and disabling bone
crises (1). Furthermore, ERT usually cannot address pa-
thology in theCNS,becauseof the inability of recombinant
enzymes to cross the blood-brain barrier (BBB). It is also
very expensive, because the limited half-life of the re-
combinant protein necessitates regular injections for the
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duration of the patient’s life and places a signiﬁcant ﬁ-
nancial burden on the healthcare system. Therefore, it is
a treatment option only in ﬁrst-world nations. Augmenta-
tion of the ability of hematopoietic stem cell therapy
(HSCT) toachievecertain therapeutic targetsby ex vivogene
therapy has enabled successful treatment of patients with
SCID and b-thalassemia major through autologous trans-
plantation (2, 3). Ex vivo gene-therapy–augmented HSCT-
based treatment is also attractive because of its potential to
tackle CNS pathology, mediated by restoration of healthy
microglia that cross into the brain and secrete therapeutic
enzymes and has been highly effective in patients who have
X-linked adrenoleukodystrophy (4) and metachromatic
leukodystrophy (5). These approaches have the potential
to treat several LSDs and diseases of the hematologic sys-
tem.However, other pleiotropic disorders affecting a wider
range of disparate body systems require an alternative
strategy. The need to develop gene therapy strategies to
address such intractable disorders is overwhelming.
Recently, patients who had hemophilia B were success-
fully treated by delivery of the human FIX (factor IX) gene
by an adeno-associated virus serotype 8 (AAV8) vector
administered intravenously (6). One of the important
outcomes of the study was that the intravenous adminis-
tration of high titers of an AAV vector was well tolerated. It
is likely that correction of a systemic pleiotropic disease will
necessitate an intravenous approach to achieve the re-
quired biodistribution.
AAV9 has received particular attention because of its
ability to cross the BBB after intravenous administration to
neonatal mice and nonhuman primates (NHPs) (7). We
have recently demonstrated that global nervous system
transduction can be achieved after in utero intravenous
administrationof this vector in fetalmiceand late-gestation
NHPs (8, 9). Considering the potential beneﬁts of fetal
therapy from the perspectives of the recipient and the
burden on vector production, perinatal gene delivery is
a suitable strategy for treating diseases when irreversible
pathology begins in utero or at birth and for conditions
affecting growth and development (10).
Little has been known about the biodistribution of AAV9
in animal models after in utero intravenous administra-
tion, other than in the nervous system. In this study,
we performed extensive systemic gene delivery after in-
travenous injection of both single-stranded (ss) and self-
complementary (sc) AAV9 to fetal and neonatal mice. A
wide variety of cell types, tissues, and organs were trans-
duced with a single dose of vector, and the degree of
transgene expression within epithelial tissues was particu-
larly striking, depending on the genome conﬁguration of
the AAV9. The global transduction observed in mice was
conﬁrmed in NHPs after intravenous administration of
scAAV9at lategestation.Aswith themice,noadverseevents
were recorded in response to high doses of vector, and
distinct transduction of epithelial cells was noted through-
out the body. Thesedata support the realistic application in
the clinic for AAV9-based perinatal gene therapy strategies
targeting multiorgan systemic disease.
MATERIALS AND METHODS
AAV vectors
AAV9 vector preparations were obtained from the University
of Pennsylvania Vector Core facility (www.med.upenn.edu/gtp/
vectorcore/). The vectors contained the cytomegalovirus (CMV)
promoter that drives expression of the green ﬂuorescent protein
(GFP) gene. The ssAAV9 also contained a woodchuck hepatitis
virus posttranscriptional regulatory element (WPRE) downstream
of the GFP gene. Both ssAAV9 and scAAV9 were titer matched to
1 3 1013 genome copies (GC)/ml for injections into fetal and
neonatal mice. scAAV9 was used at the same concentration for in-
jection into theNHP fetus at 0.9 gestational age (0.9G; 147/155 d).
Animal welfare
Mouse procedures were conducted in accordance with project
and personal licenses granted by the UK Home Ofﬁce and the
Animal (Scientiﬁc Procedures) Act of 1986. NHP procedures
were approved by and performed in strict accordance with rec-
ommendations of the Institutional Animal Care and Use Com-
mittee (IACUC) at the National University of Singapore and
Singapore Health Services Pte., Ltd. (IACUC 2009-SHS-512). All
in vivo work in NHPs was conducted at the SingHealth Experi-
mental Medicine Centre, accredited by the Association for
Assessment and Accreditation of Laboratory Animal Care Inter-
national (AAALAC). Menstruating NHP females that screened
negative for pre-existing antibodies to AAV9 were time matched
and scanned to conﬁrm pregnancy.
Administration of AAV9 vectors and stereoscopic
ﬂuorescence microscopy
Intravenous administrationof AAV9 to embryonic day (E)15 fetal
and 1 d postgestation (P1) neonatal mice has been described
previously (9). Inbrief, titermatched ss- and scAAV2/9 vectorwas
administered intravenously via the vitelline vessels to fetal mice
(20ml; 231011GC[43 1014GC/kg]). Threemiceper damwere
injected andmarkedwith colloidal carbon to identify the injected
animals (n = 3 for both ss- and scAAV9). P1 neonates were
given intravenously titer-matchedss- andscAAV9[40ml: 431011GC
(4 3 1014 GC/kg)] via the superﬁcial temporal vein (n = 3 for
both vector types). One month after the injection, vector-
administered and control (noninjected) mice underwent ter-
minal exsanguination and perfusion with PBS. This method
provided the opportunity to visualize GFP expression under
a stereoscopic ﬂuorescence microscope. Once the organs had
been examined, they were cut in half; one half was frozen and
the other half was placed in 4% paraformaldehyde (PFA).
Intravenous delivery of scAAV9 to the NHP fetus has been
described (8). In brief, injection of scAA9 was accomplished with
ultrasound-guided visualization of the intrahepatic portion of the
umbilical vein at 0.9 G (140/155 d) in time-matched pregnancies
(n = 2). Vector genomes (1 3 1013; 5 3 1013 GC/kg) were ad-
ministered in 4 ml saline according to our published technique
(11). Two live NHP neonates were delivered at 147 d by sponta-
neous vaginal delivery (NHP9001) andplanned cesarean section
(NHP 9002). Both were hand reared and at 14 and 6 wk of age,
respectively, were euthanized with isoﬂurane general anesthesia,
anoverdose of pentobarbitone, cardiac puncture, and saline/1%
PFA perfusion, in accordance with the recommendations of
Weatherall (12).Organswere collected for stereoscopic imaging,
immunohistochemistry, and vector and protein analyses. Direct
(continued from previous page)
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GFP expression in various organs was visualized with a stereoscopic
ﬂuorescence microscope (MZ16F; Leica, Wetzlar, Germany).
Representative images were captured with a DFC420 digital mi-
croscope camera and Image Analysis software (both fromLeica).
Because of the differences in the sizes of the organs, intensity of
signal, and distribution of cells of interest, the images captured
were optimized for exposure length and brightness in each case,
to capture both informative and clear images.
Immunohistochemistry and immunoﬂuorescence of
parafﬁn-embedded sections
Immunohistochemical staining for GFP on parafﬁn-embedded
tissue sections frommice was conducted by dewaxing the sections
twice in xylene for 5min followedby 2 changes of 100% industrial
methylated spirits. The sections were rinsed in deionized water,
and antigen retrieval was conducted by boiling the sections for
10min in0.01Mcitrate buffer, pH6.Endogenousperoxidasewas
depleted with 1%H2O2 in Tris-buffered saline (TBS) for 30 min.
After they were rinsed inTBS, the sections were blockedwithTBS
containing 0.3% Triton X-100 (TBS-T) and 15% normal goat
serum (NGS; Vector Laboratories, Peterborough, United King-
dom) for 30min. The sections were incubated in rabbit anti-GFP
antibodies (1:1000; Abcam, Cambridge, United Kingdom) in
TBS-T/10% NGS overnight at 4°C. They were then washed in
TBS and incubated with goat anti-rabbit IgG (1:200; Vector Lab-
oratories) in TBS-T and 10%NGS for 2 h. After they were rinsed
in TBS, the sections were incubated for 2 h in Vectastain avidin-
biotin solution (1:200; Vector Laboratories) that had been made
up in TBS 30 min before use. After the washes in TBS, visualiza-
tion of staining was achieved by exposing the sections to a 0.05%
3,39-diaminobenzidine (DAB) solution containing 0.01% H2O2.
Washing the sections twice in ice-cold TBS terminated the re-
action. The sections were then dehydrated, cleared, mounted,
and coverslipped. All DAB-stained sections were viewed under
a DM4000B light microscope (Leica), and images were captured
with a DFC 420 camera and Application Suite, version. 3.7, soft-
ware (Leica).
To conﬁrm the transduction of speciﬁc cell types, we con-
ducted immunoﬂuorescence studies on parafﬁn-embedded
sections in combination with scanning confocal microscopy.
Parafﬁn-embedded tissuesweredewaxed, andantigen retrievalwas
conducted as described above. For dual labeling of epithelial cells,
the sections were blocked with TBS-T and 15% NGS (Vector
Laboratories) for 30 min. The sections were then incubated
with rabbit anti-GFP antibody (1:1000; Abcam) andmouse anti-
pan cytokeratin antibodies (1:200; Abcam) in TBS-T and 10%
NGS overnight at 4°C. After they were rinsed in TBS, the sec-
tions were incubated in TBS-T and 10% NGS containing goat
anti-rabbit Alexa Fluor 488 and goat anti-mouseAlexa Fluor 546
(1:200; Life Technologies, Ltd., Paisley, United Kingdom) for
30 min before they were rinsed in TBS and incubated with the
nuclear stain 4,6-diamidino-2-phenylindole dihydochloride
(DAPI) (Life Technologies, Ltd.) and coverslipped with Fluo-
romountG (SouthernBiotech, Birmingham,AL,USA). The same
protocol was used to conﬁrm GFP expression in various types of
muscleﬁbers, by usingmouse anti-desmin antibodies (1:200, Dako
UK, Ltd., Cambridgeshire, United Kingdom). Images of immu-
noﬂuorescently stained sections were captured on a TCS SP5 II
confocal system with LAS AF software (Leica Microsystems, Ltd.).
As in our earlier study, PFA-ﬁxedNHP organs were imaged with
the Stereoscopic Zoom microscope SMZ1500 (Nikon, Tokyo,
Japan) with an epiﬂuorescence attachment at magniﬁcations
ranging from 30.75 to 311.25; organs from untreated animals
served as controls (8). The organs were transferred to 10% forma-
lin, parafﬁn ﬁxed, and layered onto polylysine slides at 4 mm.
Antigen retrieval was performed, as previously described. DAB
chromogen staining (with rabbit polyclonal anti-GFP antibody
ab290; Abcam UK, and Vectastain Elite ABC kit; Vector Laborato-
ries) and ﬂuorescent double-immunostaining were performed.
Tissues were colabeled with antibodies to GFP and laminin (liver
and pancreas), desmin (cardiac and skeletal muscle), and pan-
cytokeratin (epithelium), at 1:200 dilution (all from Millipore,
Singapore). Secondary goat anti-rabbit (Alexa Fluor 488) and goat
anti-mouse (Alexa Fluor 594; both from Life Technologies-
Invitrogen, Paisley, United Kingdom) antibodies were used (8).
Negative controls consisted of nontransduced NHP tissue sections
treated in thesamemanner.All imageswerecapturedonaFluoview
FV1000 scanning confocal microscope (Olympus, Tokyo, Japan).
FACS analysis
GFP expression was assessed in bone marrow samples from AAV-
injected mice by ﬂow cytometry. Bonemarrow cells were ﬂushed
from the bone with a 25-gauge syringe and resuspended in 0.1%
bovine serumalbumin inPBS.Different cell samples were stained
with anti-CD3-allophycocyanin (APC), B220-APC, or GR/Mac1-
APC (BD Pharmingen, Palo Alto, CA), and GFP expression in
each lineagewas assessedbyﬂowcytometry (CyAn,ADPAnalyzer;
Beckman Coulter Singapore Pte., Ltd.). A minimum of 2 3 104
viable cells was acquired. Off-line analysis was performed with
Summit, version 4.3, software (Dako, Glostrup, Denmark). The
presence of transgene-expressing cells was determined through
their GFP expression.
Vector biodistribution in murine and NHP tissues
The vector load was measured by quantitative (q)PCR (11). In
brief, extracted genomic DNA (15 ng) was subjected to a 25 ml
PCR reaction (SyBR Green) using forward (59-CATGGTGA-
TGCGGTTTTG-39)andreverse(59-CCTCACGACCAACTTCTG-39)
primers amplifying a 333 bp sequence at the 39-end of the CMV
promoter and the vector backbone, between the promoter
and the downstream transgene sequence (annealing tempera-
ture, 61°C). Equivalent loading was veriﬁed using forward (59-
AGTGTGACGTTGACATCCGTA-39) and reverse (59-GCCA-
GAGCAGTAATCTCCTTCT-39) primers to amplify a 112 bp
region of the murine b-actin gene. Likewise, for the NHPs,
forward (59-TCCTGTGGCATCCACGAAA-39) and reverse
(59-CCACGTCACACTTCATGATGG-39) primers were used to
amplify a 52 bp region of the macaque b-actin gene (annealing
temperature, 60°C for both reactions). Vector copies were
expressed per diploid genome [6.6 pg of DNA, vector copy
numbers (VCNs) per cell], and the calculated limit of detection
was 1 vector genome (vg) per 227 diploid genomes. Naı¨ve DNA
from nontransduced mice or NHPs served as negative controls.
GFP ELISA
GFP expression in various tissues was quantiﬁed by ELISA (8). In
brief, a primary antibody (mouse monoclonal anti-GFP; Abcam)
at 1:10,000dilution inbicarbonatebufferwasused to coat a 96-well
plate (Nunc Maxisorb; Sigma-Aldrich, St. Louis, MO, USA) over-
night. After they were washed, the plates were incubated in turn
with 300 ml/well blocking buffer (1% bovine serum albumin in
PBS), 200mg protein/well of sample or standards (serial dilutions
of GFP, starting at 4000 pg/well), 100 ml/well biotin-conjugated
secondary antibody (1:5000 inblockingbuffer;Abcam), 100ml/well
streptavidin-horseradishperoxidase (1:20,000 inblockingbuffer),
with every stage incubated at 37°C for 1 h. Tetramethylbenzidine
(100ml/well; Sigma-Aldrich) was incubated at room temperature
for 10min, with care taken to avoid exposure to direct light. Color
development was terminated using100 ml/well of 2.5 M H2SO4,
and absorbance was read at 450 nm.
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RESULTS
Widespread systemic transduction after intravenous
administration of AAV9 vectors to fetal and
neonatal mice
All AAV9 vectors contained the CMV promoter driving
GFP expression. The ssAAV9 vector differed by the in-
clusion of aWPRE sequence downstreamof theGFP gene.
The ss- and scAAV9 conﬁgurations are illustrated in Fig.
1A, B, respectively. Both sc- and ssAAV9were titermatched
to 1 3 1013 GC/ml before being administered intra-
venously to fetal and neonatal mice. One month after in-
jection, the mice were culled, together with age-matched
control noninjectedmice. The skin was removed from the
mice, and gross dissection was performed under a stereo-
scopicﬂuorescencemicroscope tovisualizeGFPexpression
directly. Widespread and extensive GFP gene expression
was observed in both the fetal and neonatal vector-
recipient mice. Representative images were taken from
Figure 1. Systemic transduction after intravenous injection of sc- and ssAAV9-GFP into fetal and neonatal mice. The ssAAV9
packaged a CMV promoter driving GFP expression with a downstream WPRE sequence. A) This expression cassette was ﬂanked
by the viral inverted terminal repeats (ITRs). B) The scAAV9 conﬁguration also packaged the CMV-GFP expression cassette but
without the WPRE sequence. The vectors were intravenously administered to fetal mice in utero via the vitelline vessels or to
neonatal mice via the superﬁcial temporal vein. One month after injection, organs were harvested and observed by stereoscopic
ﬂuorescence microscope. ssAAV9-injected fetal heart (C), neonatal liver (D), neonatal kidney (E), fetal bones in the paw (F) and
femur (G), neonatal vertebrae and ribs (H), fetal pulmonary vein (I), fetal skeletal muscle (J ), neonatal penis (K), and neonatal
testicle (L). In the same frames, scAAV9-injected and negative control neonatal diaphragm muscle (M), fetal heart (N), and
neonatal pancreas (O).
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fetal and neonatal mice injected with ssAAV9, with non-
injected mice used as controls for autoﬂuorescence. The
organwith themost prominentﬂuorescence was the heart
(Fig. 1C). However, a number of other organs and tissues
also clearly expressed GFP, such as the liver (Fig. 1D), the
kidney (Fig. 1E), andnumerous bones in thebody [e.g., the
paw (Fig. 1F), femur (Fig. 1G), vertebrae, and ribs (Fig.
1H)].GFPexpressionwasobservedalong the surfaceof the
pulmonary vein (Fig. 1I). Similar to the cardiac muscle of
theheart, skeletalmuscle throughout the body, such as the
tibialis anterior (Fig. 1J), showed prominent GFP expres-
sion. GFP expression was observed in organs of the re-
productive system, such as the penis (Fig. 1K) and testicle
(Fig. 1L). Fig. 1M–O shows gene expression in the di-
aphragm, heart, and pancreas, respectively, together with
the same organs from control noninjected mice. It is no-
table that there was markedly brighter ﬂuorescence in the
organs of mice that received ssAAV9, either in utero or as
neonates than in those that received scAAV9.
Immunohistochemical analysis of AAV9 cell type
tropism in fetal and neonatal mice
A range of tissues was taken frommice that had received ss-
or scAAV9 in utero or as neonates, and the sections were
parafﬁn embedded. Sections from these tissues were used
for immunohistochemistry with antibodies against GFP.
Visualization of the staining was achieved with DAB. Con-
trol sections were also used to assess any nonspeciﬁc
background staining. Various levels of GFP staining were
seen in all the organs and tissues collected from fetal and
neonatal vector-recipient mice when viewed under a light
microscope,andrepresentative imageswereacquired(Fig.
2A). Higher power images were also captured from a se-
lectionof tissues from themice that received vector at the 2
different stages of development (Fig. 2A, insets; ssAAV9
injection). Ahigh level of stainingwas seen throughout the
heart in all animals injected with the AAV9 vectors (Fig.
2Aa, b). The layers of the skin also showedwidespreadGFP
expression (Fig. 2Ac, d). Examination of the bladder
revealed staining,mostprominentlywithin the layers of the
muscularis propria (Fig. 2Ae, f ) and was also evident in
sections of intestine, concentrated within the villi and
muscular layerbelow the serosa (Fig. 2Ag, h).Extensiveand
widespread GFP staining was seen in skeletal muscle, such
as the quadriceps femoris (Fig. 2Ai, j). The intensity of
staining was similar to that in the cardiac muscle of the
heart, as previously described (Fig. 2Ab). Signiﬁcant stain-
ing was observed in the collecting ducts of the kidney but
also, to a lesser extent, within the glomeruli (Fig. 2Ak, l ).
GFP expressing cells were scattered throughout the thy-
mus (Fig. 2Am, n). In a fashion similar to that in the small
intestine (Fig. 2Ag, h), GFP staining was visible in the large
intestine (Fig. 2Ao, p).Examinationof the testes taken from
the male mice injected with vector showed staining at low
levels localized to the epithelial layers of the seminif-
erous tubules (Fig. 2Aq, r). Evidence of bone marrow
transduction was observed in cross-section through the
femur (Fig. 2As, t). Examination of the pancreas revealed
widespread staining with occasional darker cells clustered
together, suggesting clonal expansion (Fig. 2Au, v). Ex-
tensive staining for GFP was seen throughout the liver
(Fig. 2Aw, x). Finally, widespread staining was clearly vis-
ible in the lung in both the alveoli and the columnar
epithelium of the airways (Fig. 2Ay, z).
FACS analysis of bone marrow transduction
Bone marrow cells from four different injected neonatal
micealongsideanage-matchedcontrolnoninjectedmouse
were analyzed by ﬂow cytometry 1 mo after injection. To
assess the GFP expression in the bone marrow, the bones
were removed and the cells were ﬂushed and washed. Very
low percentages of GFP-expressing cells were observed by
ﬂuorescence-activatedcell sorting(FACS) inall theanimals
analyzed, ranging from 2.54 to 3.11% (Fig 2Bb–e), com-
pared to 0.99% in the control animal (Fig. 2Ba). Staining of
myeloid, lymphoid T, and lymphoid B cell populations to
identify GFP-positive cells in hematopoietic lineages was
also performed, but the low levels of transgene expression
in bone marrow were insufﬁcient to permit a clear distri-
bution of GFP by ﬂow cytometry (data not shown).
Quantiﬁcation of GFP expression in murine tissues
To further investigate our observation by stereoscopic
ﬂuorescence microscopy that levels of GFP expression
were higher in organs exposed to ssAAV9 than in those
exposed to scAAV9, we quantiﬁed levels of GFP. The
organs frommice that were injected as P1 neonates with ss-
or scAAV9 were removed, and GFP expression was mea-
sured by ELISA, providing a head-to-head comparison of
the levels of gene expression mediated by the 2 different
forms of AAV9 vector. Samples were analyzed from the
liver, heart, lung, kidney, skeletalmuscle (tibialis anterior),
spleen, and pancreas (Fig. 2C). Unfortunately, spleen was
not analyzed from neonatal mice that received scAAV9.
Althoughwehave studiedexpression in thenervous system
of mice injected with AAV9 vectors (9), measurements of
GFP expression in the brain was also included, to provide
an informative comparison. GFPwas detected in all organs
analyzed. The highest levels of GFPwere recorded in heart
and skeletal muscle, conﬁrming our observations when ex-
amining the whole organs under the stereoscopic ﬂuores-
cence microscope and by immunohistochemistry. However,
impressive levels ofGFPwerealsomeasured in the liver, lung,
kidney, and pancreas. The lowest level of GFP was found in
the spleen, which received ssAAV9. In all organs other than
the heart and spleen (no spleen from scAAV9-administered
mice for comparison available), the expression of GFP was
signiﬁcantly higher in those mice receiving ssAAV9 when
compared to those receiving scAAV9 (n = 3 per group;
P,0.05;usingANOVAandposthocBonferronicomparison).
Immunoﬂuorescence and scanning confocal
microscopy conﬁrmation of cell type tropism in fetal
and neonatal mice
Direct visualization of GFP expression in organs by ste-
reoscopic ﬂuorescence and light microscopy examination
of immunoperoxidase-stained sections suggested that
AAV9 has a strong tropism for muscle ﬁbers and also epi-
thelial cells ina rangeoforgans.Toconﬁrmthisobservation,






Figure 2. Detection of gene expression in a variety of organs and tissues by immunohistochemistry, FACS analysis, and ELISA.
Organs from vector-recipient fetal and neonatal mice were harvested 1 mo after injection, and parafﬁn-embedded sections were
examined by immunohistochemistry with antibodies against GFP and by DAB staining. Negative control and neonatally ssAAV9-
injected heart (Aa, Ab), skin (Ac, Ad), bladder (Ae, Af), intestine (Ag, Ah), skeletal muscle (Ai, Aj), kidney (Ak, Al), thymus (Am,
An), large intestine (Ao, Ap), testicle (Aq, Ar), and liver (As, At) and negative control and in utero injected pancreas (Au, Av), liver
(Aw, Ax), and lung (Ay, Az). FACS analysis of bone marrow (%GFP against side-scatter plot) from neonatally injected mice (B)
revealed low-level transduction ranging from 2.25 to 3.11% above background of 0.99% in noninjected controls (Ba). GFP ELISA
quantiﬁed gene expression in organs of neonatal mice receiving intravenously injected, titer-matched ss- and scAAV9. C) In all
organs, with the exception of the heart and spleen (scAAV9 data not collected), ssAAV9 induced signiﬁcantly higher levels of
GFP gene expression. ANOVA and post hoc Bonferroni comparison (n = 3). *P , 0.05.
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immunoﬂuorescence with cell-speciﬁc antibodies against
epithelium and muscle was used in conjunction with
antibodies against GFP. Antibodies against cytokeratin
and the structural protein desmin were used to label
epithelial cells and muscle ﬁbers, respectively. DAPI was
used to label genomic DNA and highlight the cell nuclei.
Scanning confocal microscopy was then used to visualize
the ﬂuorescently labeled cells and GFP expression to
look for colocalization of signal, therefore, conﬁrming
expression of the transgene in these speciﬁc cell types.
Representative images were taken of various tissues from
mice injected in utero or as P1 neonates with ssAAV9 (Fig.
3). As a negative control and to assess nonspeciﬁc back-
ground staining, the sections were labeled by the same
procedure as was used for all other tissues, but they were
not exposed to primary antibodies. Very little back-
ground staining was detected. An example of this is
shown in sections of skin taken from mice injected as
neonates with ssAAV9, whereDAPI was clearly visible and
labeled the cell nuclei blue (Fig. 3Aa). Very little back-
ground staining was seen in the red (Fig. 3Ab) or green
(Fig. 3Ac) channel. Themerging of the channels is shown
in Fig. 3Ad. Immunoﬂuorescent labeling of the skin
taken from mice injected as neonates with DAPI (Fig.
3Ae), antibodies against cytokeratin in red (Fig. 3Af )
andGFP in green (Fig. 3Ag), revealed labeling of epithelium
andextensiveGFPexpressionthroughout thetissue.Merging
of the signals revealed colocalization of cytokeratin-labeled
A B
a' b'
Figure 3. Immunoﬂuorescence and scanning confocal microscopy show cellular tropism of AAV9 after in utero and neonatal
intravenous injection of ssAAV9 vector in mice. Parafﬁn-embedded sections of organs were ﬂuorescently labeled with DAPI (blue
channel) to visualize the nuclei, anti-GFP antibodies (green channel) to highlight AAV-mediated gene expression, and anti-
pancytokeratin antibodies to label epithelial cells. Representative images were merged to examine colocalization of signals
(yellow or pink). Aa–Ad) Negative control sections of skin demonstrate minimal background signal from either antibody. GFP
was expressed to various extents in all organs and tissues. Signiﬁcant colocalization of GFP and cytokeratin in skin (Ae–Ah); none
in small intestine (Ai–Al); signiﬁcant in the large intestine (Am–Ap), bladder (Aq–At), and testes (Au–Ax); none in lung
(Ay–Ab9). Parafﬁn-embedded muscle tissue sections were stained with DAPI and anti-GFP, but also with anti-desmin antibodies to
label muscle ﬁbers (red channel). Ba–Bd) Minimal background signal in negative control sections of heart. Strong, widespread
GFP expression in sections of the heart from ssAAV9-injected mice clearly colocalized in desmin-labeled cardiac muscle (Be–Bh),
skeletal muscle (Bi–Bl), and muscle from the diaphragm (Bm–Bp). Scale bars = 75 mm.
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epithelial cells and GFP expression as pink (where strong
red channel signal representing cytokeratin merged with
lighter GFP green channel signal) and yellow (where
strong red and green channel signals merged) (Fig. 3Ah).
Sections of the small intestine taken from mice injected
with vector as neonates were labeled with DAPI (Fig. 3Ai)
and cytokeratin that labeled the columnar epithelium of
the villi (Fig. 3Aj). GFP was strongly labeled, most promi-
nently in cells closer to the luminal surface (Fig. 3Ak). The
ﬂuorescence gradually decreased in intensity with in-
creasing distance from the lumen. Merging of the signals
produced colocalization of yellow signal in the cells (Fig.
3Al). Sections of the large intestine frommice injected as
neonates were also examined. The sections were stained
with DAPI (Fig. 3Am) and antibodies against cytokeratin,
which, in a fashion similar to that seen in the small intestine
(Fig. 3Aj), labeled the columnar epithelial cells of the villi
(Fig. 3An). However, unlike the small intestine (Fig. 3Ak),
GFP expression was more uniform in its distribution
through the villi and also within the muscular layers (Fig.
3Ao). Merging of the signals revealed strong colocalization
of red and green channel signals, producing yellow signal
that lined the surface of the villi, in a pattern typical of
epithelial cell distribution in the lumen of the intestine
(Fig. 3Ap). Sections of the bladder frommice injected with
vector in utero were stained with DAPI (Fig. 3Aq) and anti-
bodies against cytokeratin that speciﬁcally labeled the
urothelial cells lining the luminal surface (Fig. 3Ar). Anti-
bodies against GFP also labeled cells of the luminal surface
(Fig. 3As). Merging of the signals produced a pink color
conﬁrming GFP expression in the urothelium of the
bladder (Fig. 3At). Sections of the testes taken from mice
that were injected as neonates were also stained withDAPI
(Fig. 3Au). Antibodies against cytokeratin clearly labeled
the columnar epithelium lining the coiled tubules of the
epididymis (Fig. 3Av). Antibodies against GFP revealed
expression within the walls of the epididymis (Fig. 3Aw).
The merging of the signals produced a pink color within
the lumenof the tubulesof theepididymis, conﬁrmingGFP
expression within the columnar epithelial layer (Fig. 3Ax).
Sections of lung taken frommice injected as neonates were
stainedwithDAPI (Fig. 3Ay), antibodies against cytokeratin
(Fig. 3Az), and antibodies against GFP (Fig. 3Aa9). Al-
thoughboth cytokeratin andGFPwere clearly detected, no
obvious colocalization was observed (Fig. 3Ab9).
For evaluation of the muscle, as a negative control, sec-
tions from the heart from animals injected with vector as
neonates were taken and stained by using the sameprotocol
as all other tissues, but with no primary antibody against
desminorGFP.Very little background stainingwasdetected.
An example shows sections of heart where DAPI was clearly
visible with the cell nuclei labeled blue (Fig. 3Ba). Very little
background staining was seen in the red (Fig. 3Bb) or the
green (Fig. 3Bc) channel. The merging of the channels is
shown in Fig. 3Bd. Cardiac, skeletal, and diaphragmmuscles
were examined from tissue sections taken from injected
mice stainedwithDAPI (Fig. 3Be, i, andm, respectively). The
tissues were also ﬂuorescently labeled with anti-desmin
antibodies (Fig. 3Bf, j, and n). Extensive GFP staining was
observed throughout all 3 types of muscle tissue, with ﬂuo-
rescently labeledanti-GFPantibodies (Fig.3Bg,k, and o).The
mergingofall 3 channels revealedextensivecolocalizationof
signals in the musculature (Fig. 3Bh, l, and p).
Systemic transduction after intravenous
administration of scAAV9 to the late-gestation NHPs
scAAV9 (a total of 13 1013 vg) was injected intravenously
into 2 fetal macaques at 0.9 G, using ultrasound-guided
visualization of the intrahepatic portion of the umbilical
vein. Fig. 4A shows a labeled image captured from the ul-
trasound scan during the procedure that highlights the
position of the fetal liver, intrahepatic vein, needle, and
needle tip. Fig. 4B further highlights the hepatic vein via
turbulencemeasurements of blood ﬂow. Two infants were
delivered at 147 d andhand reared.Onewas euthanized at
14wk (NHP9001) of age and the other at 6wk. Theorgans
were collected, and GFP expression was directly visualized
under a stereoscopic ﬂuorescence microscope. Robust
GFP expression was observed in almost all viscera and
across skeletal and cardiacmuscles. StrongGFP expression
was demonstrated by stereoscopic ﬂuorescence imaging,
withparticularly robust expression in all layers of theheart,
especially the cardiac muscle of the myocardium and as-
cending aorta (Fig. 4C), limbs (Fig. 4D), renal cortex (Fig.
4E),paws (Fig. 4F), tongue(Fig.4G), skeletalmusclesof the
diaphragm (Fig. 4H), and intercostal spaces (Fig. 4I). Ex-
pression was also present in the viscera, including the
spleen (Fig. 4K) andpancreas (Fig 4L), whereas less robust
expression was observed on imaging of the liver (Fig. 4J).
Conﬁrmation of cellular tropism in the fetal NHPs
by immunoﬂuorescence and scanning
confocal microscopy
Cellular distribution of GFPwas obvious after costaining of
specimens with cell-speciﬁc antibodies. As observed in the
mouse studies, the epithelia were extensively transduced
body-wide and identiﬁed with a pan-cytokeratin antibody.
GFP was strongly expressed in epithelia throughout the
respiratory tract and colocalized with the pan-cytokeratin
marker from the ciliated tracheal lining (Fig. 5Ae–h) and
bronchus (Fig. 5Ai–l) to the lung alveoli (Fig. 5Am–p).
Furthermore, there was GFP expression within the pan-
creas (Fig. 5Aq–t) and extensive expression within the
mucosal lining of the intestines (Fig. 5Au–x), the skin
(Fig. 5Ay–b9), and testes (Fig. 5Ac9–f 9), all of which colo-
calized with the pan-cytokeratin marker. Transduced mus-
cle cells were colabeled with GFP and desmin antibodies in
the skeletal muscle of the locomotor system. Negative
control sections demonstrated minimal background signal
from either antibody (Fig. 5Ba–d). Signiﬁcant colocaliza-
tion of signal was seen in skeletal muscle cells (Fig. 5Be–h)
and in the heart (Fig. 5Bi–l ). Several GFP-expressing cells
in the pancreas colocalized expression with signal from
insulin antibody-labeled cells (Fig. 5Ce–h) and GFP signal
also colocalized with laminin labeled cells within the liver
(Fig. 5De–h). Negative control sections demonstrated min-
imal background signal using either antibody (Fig. 5Ca–d).
VCN and total GFP analysis in NHP tissues and organs
The VCN was measured by qPCR in tissues harvested
from theNHPs that received fetal intravenous injections
of scAAV9. Although we have reported on transduction
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of the CNS by intravenous administration of an AAV9
vector to late-gestation NHPs (8), we also included data
from the cerebrum and the cerebellum as an infor-
mative comparison. There was a global distribution of
vector in all organs analyzed, with a wide range of VCNs
observed (Fig. 5E). Mostly, the organs showed VCNs in
the range of 100–600 copies/cell. Skeletal muscle and
aorta, skin, fat, and viscera (liver, pancreas, adrenal
gland, and spleen) demonstrated the heaviest vector
load, with a range of 1000–4000 copies/cell.
Figure 4. Systemic transduction after ultrasound-guided intravenous injection of scAAV9 into the hepatic portion of the umbilical
vein in late-gestation and fetal macaques. A) Relative positions of the fetal liver, intrahepatic vein, needle, and needle tip within
the vein. B) Blood ﬂow turbulence, highlighting ﬂow through the intrahepatic vein. Organs were harvested and examined by
stereoscopic ﬂuorescence microscopy. Extensive systemic GFP expression in the heart (C), skeletal muscle (D), kidney (E), paws
(F), tongue (G), musculature of the diaphragm (H), intercostal space (I), and visceral organs, such as the liver (J ), spleen (K),
and pancreas (L).
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Figure 5. Immunoﬂuorescence and scanning confocal microscopy analysis of AAV9 cell tropism, ELISA quantiﬁcation of GFP
expression, and qPCR analysis of the VCNs in organs and tissues of late-gestation intravenously injected macaques with AAV9
vector. Sections of organs and tissues harvested from macaques that received scAAV9 were ﬂuorescently labeled with DAPI to
detect the cell nuclei (blue channel) and anti-GFP antibodies (green channel) and anti-pancytokeratin antibodies to label
epithelial cells (red channel). Aa–Ad) Negative control sections from the trachea show minimal background signal from both
(continued on next page)
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There was also a striking difference in VCNbetween the
2 time points, possibly due to the loss of episomal AAV.
Overall, the VCNs were 1 to 3 log-fold lower between 6 and
14 wk, with the steepest drop in observed in the viscera,
stomach, and thymus (Fig. 5E).
Absolute GFP content was measured by ELISA and,
whenexpressed as a ratioof total protein,was similar across
all tissues, in the range of 103–104 pg/mg protein in both
recipients (Fig. 5F). However, because of the higher VCN
in NHP 9002 at the earlier time point of harvest, GFP
density per vector copy was several fold lower at 6 wk com-
pared with 14 wk (Fig. 5F).
DISCUSSION
This study demonstrates that AAV9 mediates widespread
and systemic gene expression, in mice and NHPs, after
perinatal intravenous administration. Further adding to
our previous studies documenting nervous system trans-
duction in both species (8, 9), in this study, we examined
extensive transduction of a variety of organs and tissues
involved in the skeletal, muscular, cardiovascular, gastro-
intestinal, urinary, endocrine, digestive, and reproductive
systems.
The data suggest that, aside from the AAV9 that is se-
questered in liver Kupffer cells and other resident macro-
phages, a sufﬁcient level remains in circulation tomediate
very effective transduction of other tissues. This level allows
for systemic biodistribution, which we have measured in
both mice and NHPs by direct detection of viral particles
and reporter gene expression. The highest levels of re-
porter gene expression are found in the musculature
(cardiac and skeletal) in both species. This result supports
those from a study in older mice of efﬁcient gene delivery
to themuscle after systemic administrationofAAV9 (13). It
is notable that there was distinct transduction of epithelia
in various organs examined by immunoﬂuorescence and
scanning confocal microscopy. Limberis et al. (14) have
demonstrated that several AAV serotypes, includingAAV9,
have the ability to transduce the airway epithelium after
instillation into the mouse lung. Haddad et al. (15) have
also recently shown that AAV9 mediates transduction of
the choroid plexus epithelia in the brain after in utero
intracerebroventricular administration. However, in our
study, we found that intravenous administration of AAV9
mediated a far more systemic transduction of epithelia.
This ﬁnding is of consequence for diseases such as cystic
ﬁbrosis, where therapeutic expression is required in the
epithelia of visceral tissues, such as the intestines and in the
airways and it may also be of signiﬁcance in developing
gene therapy strategies for skin conditions where gene
delivery to a large surface area has been technically chal-
lenging. It is also surprising, given that other studies have
achieved epithelial transduction after delivery to the apical
surface. In contrast, we have observed this effect after in-
travenous injection, where traversal of the endothelium
anddelivery to thebasolateral surfaceof theepitheliumare
likely to occur through processes such as transcytosis (16).
Weconductedadirect comparison inmiceofAAV9with
a self-complementary genome lacking a WPRE sequence
versus a single-stranded genome with a WPRE sequence
downstream of the GFP gene. Our data suggest that the
single-stranded form with a WPRE sequence mediates
higher levels of gene expression when compared to the
self-complementary version without WPRE. This result
supports our previous observations of gene expression in
the brain using these 2 vectors and administered via the
same route and age (9). Because our data do not include
an ssAAV9 that lacks the WPRE sequence, meaningful
comparisons cannot be made, and so further studies
designed to speciﬁcally address and investigate these
questions are needed. The AAV9 vectors used in this study
contained theCMVpromoterdrivingGFPgeneexpression.
Although this promoter mediates strong and ubiquitous
geneexpression, its viral originwillmake its long-termuse
in mammals unsuitable and prone to gene silencing over
time (17). A promoter of mammalian origin is needed
that can mediate long-term systemic gene expression.
Several candidate mammalian promoters are available,
such as those that drive housekeeping genes, but each
must be tested individually in AAV9 to ascertain whether
they can also mediate systemic expression.
Sustained and robust gene expression was observed
1 mo after administration to the mouse in the fetal or
neonatal period, both times of intense growth and cellular
proliferation. AAV vectors are considered to be non-
integrating, and the genome would be maintained as epi-
somes in the transduced cell. Therefore, as the cell divides
the episomes would be diluted in progeny cells, leading to
agradual loss in geneexpression.The sustainedand strong
expression we observe could be explained by the relatively
high doses of virus we administered to both species. This
effect is reﬂected in the high number of vector genomes
that we have measured in various harvested organs that
decrease substantially within a short time.Of note, we have
not observed any adverse effects in both species to such
high AAV9 doses or to the strong GFP expression and all
administered animals develop and gain weight as usual.
Histologic analyses of organs showed normal structural
architecture and absence of cellular inﬂammatory im-
mune response. These observations support results of our
previous studies where we demonstrated no inﬂammatory
response in the brain after administration of the same
anti-GFP and anti-pancytokeratin antibodies. Signiﬁcant GFP expression was seen in the airway tissues that colocalized with
epithelium labeled with pancytokeratin antibodies producing a yellow or pink signal, in trachea (Ae–Ah), bronchus (Ai–Al), and
lung alveoli (Am–Ap). Colocalization of GFP expression and epithelial marker was observed in the pancreas (Ae–Ah), intestine
(Au–Ax), skin (Ay–Ab9), and testes (Ac9–Af9). To conﬁrm muscle tropism, sections were labeled with antidesmin antibodies.
Ba–Bd) Negative control sections from skeletal muscle show minimal background signal from the green and red channels. Clear
colocalization between GFP- and desmin-labeled cells is shown in skeletal (Be–Bh) and cardiac muscle (Bi–Bk). Anti-GFP
antibodies colocalized in cells labeled with anti-insulin antibodies in the pancreas (Ce–Ch) and in insulin-labeled cells in the liver
(De–Dh). E) qPCR analysis of macaque organs and tissues harvested at 6 and 14 wk and expressed as vector copies per 6.6 pg of
DNA. F) GFP expression quantiﬁed by ELISA of various tissues and standardized against the VCN.
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doses of vector via the same routeof administration inboth
species (8, 9).Theabsenceof any obvious adverse effects to
such large amounts of a nonmammalian protein such as
GFP is possibly a consequence of gene expression during
the perinatal period when the immune system is still naı¨ve.
Immune tolerance to the exogenous protein may be ach-
ieved, as has been demonstrated byWaddington et al. (18),
whoused factor IX in amousemodelof hemophiliaB.The
ability to induce tolerance to proteins to which the body is
naı¨ve is a potential advantage for clinical translation.
Patients with severe gene mutations or deletions may ex-
press little or no protein. Gene therapy in older patients
with a fully mature immune system may result in elimina-
tion of expressed protein from the body, negating any
therapeutic beneﬁt. However, longer-term studies in the
NHPmodel would be highly desirable for 2 main reasons:
ﬁrst, we observed a reduction inGFP levels in organs taken
from the older NHP compared to those taken from the
younger one. To what extent this continues with age is
unknown. Second, Chandler et al. (19) have robustly de-
monstrated the importance of longer-term observation
when using systemically administered AAV vectors during
the neonatal period to monitor for hepatic genotoxicity.
Both of these considerations should be essential compo-
nents of a preclinical study.
The further advantages of perinatal gene therapy are
numerous and have been reviewed in greater detail else-
where (20–23). In addition to an increased vector-to-cell
ratio and the opportunity to transduce a greater stem cell
population, a systemic gene therapy approach that can be
administered during the perinatal period is particularly
attractive for those diseases where progressive and irre-
versible pathologymanifests early in development and is of
importance in preventing loss of cells with limited capacity
to regenerate (e.g., neurons in the brain). Early-childhood
neurodegenerative diseases such as type II GD fall into this
categorywhere brain pathology is present at birth (24) and
canbe accompaniedby visceral pathology. ERT is available
to treat hepatosplenomegaly but is ineffective against CNS
disease. The lack of any clinical protocol to treat type II
patients with GD and the ﬁnancial burden associated with
ERT make a unifying systemic treatment with perinatally
administered AAV9-mediated gene therapy an essential
and economically viable solution. A further advantage that
perinatal administration of gene therapy may have for
systemic administration is that the late-gestation fetus or
neonate is unlikely tohavebeen exposed toAAV, obviating
the neutralizing effect of pre-existing antibodies. Calcedo
et al. (25) have shown that neutralizing antibodies to AAV2
and -8 are present at relatively high levels in blood plasma
of neonates. However, the study suggests that this is un-
likely to be caused by the intrauterine transmission of
maternal AAV or infection during vaginal birth, because
there is no persistent humoral response to AAV at birth.
The same study concludes that AAV infections are likely
to begin at 1 year of age and peak at 3 years of age.
Therefore, to avoid the questionofmaternal neutralizing
antibodies to any particular AAV vector serotype, it may
be necessary to screen the mother for antibodies against
the relevant AAV serotype. Most of the population have
been exposed, to some extent, to various serotypes of
wild-type AAV and so are likely to mount a humoral im-
mune response to the vector if they are serotype positive.
Boutin et al. (26) have shown that 47% of the population
is positive for anti-AAV9 total IgGs. This number may
exclude some older patients from future clinical trials
involving systemic delivery of AAV9, whereas it is unlikely
to be an issue in perinatal gene therapy.
Cordocentesis (also known as percutaneous umbilical
cord blood sampling) was used to administer AAV9 in utero
to late-gestation macaques. This procedure is an estab-
lished one conducted around the world to withdraw blood
for analysis or to deliver blood transfusions andmedication
via the umbilical cord (27). This study provides evidence
that intravenously administered inuterogene therapy is safe
when used in an established clinical protocol commonly
practiced in obstetrics departments around theworld. This
consideration is important in assessing the feasibility of
fetal gene therapy for clinical use. Intravenous adminis-
tration of AAV9 has been conducted in neonatal mac-
aques, resulting in widespread transduction of various
organs (28). In the absence of a direct head-to-head com-
parison, it is unknownwhether the fetal approach results in
greater transduction efﬁciencies than neonatal adminis-
tration, but it conﬁrms that the galactose receptor, re-
quired for AAV9 transduction (29, 30), is present on the
surface of cells at this early stage of development in NHPs.
In summary, this study demonstrates that AAV9 can
mediate systemic gene delivery after in utero and neonatal
intravenous administration to mice and late-gestation
macaques. Although the cardiac and skeletal muscula-
ture showed the highest levels of gene expression, all
organs examined were transduced, particularly in the epi-
thelial cell populations. The highest levels of gene expres-
sion were achieved with ssAAV9, which contains a WPRE
sequence downstream of the transgene. No adverse effects
were observed to the relatively high levels of AAV9 admin-
istered to the mice or NHPs. The safe administration of
AAV9 to fetal NHPs by using a clinically approved protocol
supports the development of minimally invasive in-
travenous fetal gene therapy for patients with pleiotropic
diseases that manifest pathologic characteristics at birth or
during in utero development. It is noteworthy that, with the
useof existingdiagnostic technologies, thereare challenges
to be met in identifying the genetic defect in utero, the po-
tential target cohort of diseases therefore may be limited.
However, as diagnostic technologies develop, the number
of amenable diseases that can be identiﬁed and treated by
this approach will increase.
This work was supported by the UK Medical Research
Council Grant G1000709. A.A.R. and S.N.W. have also
received support from the UK Gauchers Association. A.A.R.
received support from the Niemann-Pick Disease Group and
National Brain Iron Accumulation Disorders Association.
REFERENCES
1. Goker-Alpan, O. (2011) Therapeutic approaches to bone pathology
in Gaucher disease: past, present and future.Mol. Genet. Metab. 104,
438–447
2. Cavazzana-Calvo,M., Payen, E., Negre,O.,Wang,G.,Hehir, K., Fusil,
F., Down, J., Denaro, M., Brady, T., Westerman, K., Cavallesco, R.,
Gillet-Legrand, B., Caccavelli, L., Sgarra, R., Maouche-Chre´tien, L.,
Bernaudin, F., Girot, R., Dorazio, R., Mulder, G. J., Polack, A., Bank,
A., Soulier, J., Larghero, J., Kabbara,N.,Dalle, B.,Gourmel, B., Socie,
G., Chre´tien, S., Cartier, N., Aubourg, P., Fischer, A., Cornetta, K.,
AAV9 SYSTEMIC GENE DELIVERY TO MICE AND MACAQUES 3887
Galacteros, F., Beuzard, Y., Gluckman, E., Bushman, F., Hacein-




J., Brouns, G., Schmidt, M., Von Kalle, C., Barington, T., Jakobsen,
M. A., Christensen,H.O., Al Ghonaium, A., White, H. N., Smith, J. L.,
Levinsky, R. J., Ali, R. R., Kinnon, C., and Thrasher, A. J. (2004) Gene
therapy of X-linked severe combined immunodeﬁciency by use of
a pseudotyped gammaretroviral vector. Lancet 364, 2181–2187
4. Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C. C., Veres, G.,
Schmidt, M., Kutschera, I., Vidaud, M., Abel, U., Dal-Cortivo, L.,
Caccavelli, L., Mahlaoui, N., Kiermer, V., Mittelstaedt, D., Bellesme,
C., Lahlou, N., Lefre`re, F., Blanche, S., Audit, M., Payen, E.,
Leboulch, P., l’Homme, B., Bougne`res, P., Von Kalle, C., Fischer, A.,
Cavazzana-Calvo, M., and Aubourg, P. (2009) Hematopoietic stem
cell gene therapy with a lentiviral vector in X-linked adrenoleuko-
dystrophy. Science 326, 818–823
5. Bifﬁ, A., Montini, E., Lorioli, L., Cesani, M., Fumagalli, F., Plati, T.,
Baldoli, C., Martino, S., Calabria, A., Canale, S., Benedicenti, F.,
Vallanti, G., Biasco, L., Leo, S., Kabbara, N., Zanetti, G., Rizzo,W. B.,
Mehta, N. A., Cicalese, M. P., Casiraghi, M., Boelens, J. J., Del Carro,
U., Dow, D. J., Schmidt, M., Assanelli, A., Neduva, V., Di Serio, C.,
Stupka, E., Gardner, J., von Kalle, C., Bordignon, C., Ciceri, F.,
Rovelli, A., Roncarolo, M. G., Aiuti, A., Sessa, M., and Naldini, L.
(2013) Lentiviral hematopoietic stem cell gene therapy beneﬁts
metachromatic leukodystrophy. Science 341, 1233158
6. Nathwani, A. C., Tuddenham, E. G., Rangarajan, S., Rosales, C.,
McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J.,
Harrington,C.,O’Beirne, J., Smith, K., Pasi, J., Glader,B., Rustagi, P.,
Ng, C. Y., Kay, M. A., Zhou, J., Spence, Y., Morton, C. L., Allay, J.,
Coleman, J., Sleep, S., Cunningham, J. M., Srivastava, D.,
Basner-Tschakarjan, E., Mingozzi, F., High, K. A., Gray, J. T., Reiss,
U. M., Nienhuis, A. W., and Davidoff, A. M. (2011) Adenovirus-
associated virus vector-mediated gene transfer in hemophilia B. N.
Engl. J. Med. 365, 2357–2365
7. Foust, K. D., Wang, X., McGovern, V. L., Braun, L., Bevan, A. K.,
Haidet, A. M., Le, T. T., Morales, P. R., Rich, M. M., Burghes, A. H.,
and Kaspar, B. K. (2010) Rescue of the spinal muscular atrophy
phenotype in amousemodel byearly postnatal delivery of SMN.Nat.
Biotechnol. 28, 271–274
8. Mattar, C. N., Waddington, S. N., Biswas, A., Johana, N., Ng, X. W.,
Fisk, A. S., Fisk, N. M., Tan, L. G., Rahim, A. A., Buckley, S. M., Tan,
M. H., Lu, J., Choolani, M., and Chan, J. K. (2013) Systemic delivery
of scAAV9 in fetal macaques facilitates neuronal transduction of the
central and peripheral nervous systems. Gene Ther. 20, 69–83
9. Rahim, A. A., Wong, A. M., Hoefer, K., Buckley, S. M., Mattar, C. N.,
Cheng, S. H., Chan, J. K., Cooper, J. D., Waddington, S. N. (2011)
Intravenous administration of AAV2/9 to the fetal and neonatal
mouse leads to differential targeting of CNS cell types and extensive
transduction of the nervous system. FASEB J. 25, 3505–3518
10. Mattar, C.N., Choolani,M., Biswas,A.,Waddington, S.N., andChan,
J. K. (2011) Fetal gene therapy: recent advances and current
challenges. Expert Opin. Biol. Ther. 11, 1257–1271
11. Mattar, C. N., Nathwani, A. C., Waddington, S. N., Dighe, N.,
Kaeppel, C., Nowrouzi, A., Mcintosh, J., Johana, N. B., Ogden, B.,
Fisk, N. M., Davidoff, A. M., David, A., Peebles, D., Valentine, M. B.,
Appelt, J. U., vonKalle, C., Schmidt,M., Biswas, A., Choolani,M., and
Chan, J. K. (2011) Stable human FIX expression after 0.9G
intrauterine gene transfer of self-complementary adeno-associated
viral vector 5 and 8 in macaques.Mol. Ther. 19, 1950–1960
12. Weatherall, D. J. (2006) The Use of Non-human Primates in Research,
Academy of Medical Sciences, London
13. Katwal, A. B., Konkalmatt, P. R., Piras, B. A., Hazarika, S., Li, S. S.,
JohnLye,R., Sanders, J.M., Ferrante, E.A., Yan, Z., Annex, B.H., and
French, B. A. (2013) Adeno-associated virus serotype 9 efﬁciently
targets ischemic skeletal muscle following systemic delivery. Gene
Ther. 20, 930–938
14. Limberis, M. P., Vandenberghe, L. H., Zhang, L., Pickles, R. J., Wil-
son, J. M. (2009) Transduction efﬁciencies of novel AAV vectors in
mouse airway epithelium in vivo and human ciliated airway epithe-
lium in vitro.Mol. Ther. 17, 294–301
15. Haddad, M. R., Donsante, A., Zerfas, P., Kaler, S. G. (2013) Fetal
brain-directed AAV gene therapy results in rapid, robust, and per-
sistent transduction of mouse choroid plexus epithelia. Mol. Ther.
Nucleic Acids 2, e101
16. Di Pasquale, G., and Chiorini, J. A. (2006) AAV transcytosis through
barrier epithelia and endothelium.Mol. Ther. 13, 506–516
17. Paterna, J. C., Moccetti, T., Mura, A., Feldon, J., and Bu¨eler, H.
(2000) Inﬂuence of promoter and WHV post-transcriptional regu-
latory element on AAV-mediated transgene expression in the rat
brain. Gene Ther. 7, 1304–1311
18. Waddington, S. N., Buckley, S. M., Nivsarkar, M., Jezzard, S.,
Schneider, H., Dahse, T., Kemball-Cook, G., Miah, M., Tucker, N.,
Dallman, M. J., Themis, M., and Coutelle, C. (2003) In utero gene
transfer of human factor IX to fetal mice can induce postnatal
tolerance of the exogenous clotting factor. Blood 101, 1359–1366
19. Chandler, R. J., LaFave, M. C., Varshney, G. K., Trivedi, N. S.,
Carrillo-Carrasco, N., Senac, J. S., Wu, W., Hoffmann, V., Elkahloun,
A. G., Burgess, S. M., and Venditti, C. P. (2015) Vector design
inﬂuences hepatic genotoxicity after adeno-associated virus gene
therapy. J. Clin. Invest. 125, 870–880
20. Buckley, S. M., Rahim, A. A., Chan, J. K., David, A. L., Peebles, D.M.,
Coutelle, C., Waddingtont, S. N. (2011) Recent advances in fetal
gene therapy. Ther. Deliv. 2, 461–469
21. Coutelle, C., andWaddington, S. N. (2012) The concept of prenatal
gene therapy.Methods Mol. Biol. 891, 1–7
22. David, A. L., and Peebles, D. (2008) Gene therapy for the fetus: is
there a future? Best Pract. Res. Clin. Obstet. Gynaecol. 22, 203–218
23. Mattar, C. N., Waddington, S. N., Biswas, A., Davidoff, A. M.,
Choolani, M., Chan, J. K., and Nathwani, A. C. (2012) The case for
intrauterine gene therapy. Best Pract. Res. Clin. Obstet. Gynaecol. 26,
697–709
24. Orvisky, E., Sidransky, E., McKinney, C. E., Lamarca, M. E., Samimi,
R., Krasnewich, D., Martin, B. M., and Ginns, E. I. (2000)
Glucosylsphingosine accumulation in mice and patients with
type 2 Gaucher disease begins early in gestation. Pediatr. Res. 48,
233–237
25. Calcedo, R., Morizono, H., Wang, L., McCarter, R., He, J., Jones, D.,
Batshaw, M. L., and Wilson, J. M. (2011) Adeno-associated virus an-
tibody proﬁles in newborns, children, and adolescents. Clin. Vaccine
Immunol. 18, 1586–1588
26. Boutin, S., Monteilhet, V., Veron, P., Leborgne, C., Benveniste, O.,
Montus,M. F., andMasurier, C. (2010) Prevalence of serum IgGand
neutralizing factors against adeno-associated virus (AAV) types 1, 2,
5, 6, 8, and9 in thehealthy population: implications for gene therapy
using AAV vectors.Hum. Gene Ther. 21, 704–712
27. Society for Maternal-Fetal Medicine (SMFM), Berry, S. M., Stone, J.,
Norton, M. E., Johnson, D., and Berghella, V.; (2013) Fetal blood
sampling. Am. J. Obstet. Gynecol. 209, 170–180
28. Bevan, A. K., Duque, S., Foust, K. D., Morales, P. R., Braun, L.,
Schmelzer, L., Chan, C. M., McCrate, M., Chicoine, L. G., Coley, B.
D., Porensky, P. N., Kolb, S. J., Mendell, J. R., Burghes, A. H., Kaspar,
B. K. (2011) Systemic gene delivery in large species for targeting
spinal cord, brain, andperipheral tissues for pediatric disorders.Mol.
Ther. 19, 1971–1980
29. Bell, C. L., Vandenberghe, L. H., Bell, P., Limberis, M. P., Gao, G. P.,
Van Vliet, K., Agbandje-McKenna, M., andWilson, J. M. (2011) The
AAV9 receptor and its modiﬁcation to improve in vivo lung gene
transfer in mice. J. Clin. Invest. 121, 2427–2435
30. Shen, S., Bryant, K. D., Brown, S. M., Randell, S. H., and Asokan, A.
(2011) Terminal N-linked galactose is the primary receptor for
adeno-associated virus 9. J. Biol. Chem. 286, 13532–13540
Received for publication April 16, 2015.
Accepted for publication May 26, 2015.
3888 Vol. 29 September 2015 MATTAR ET AL.The FASEB Journal x www.fasebj.org
